Ropes Wealth Advisors buys $2,264,182 stake in AbbVie Inc (ABBV)

AbbVie Inc (ABBV) : Ropes Wealth Advisors scooped up 1,162 additional shares in AbbVie Inc during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Aug 8, 2016. The investment management firm now holds a total of 33,819 shares of AbbVie Inc which is valued at $2,264,182.AbbVie Inc makes up approximately 0.77% of Ropes Wealth Advisors’s portfolio.

Other Hedge Funds, Including , Assetmark Inc boosted its stake in ABBV in the latest quarter, The investment management firm added 1,344 additional shares and now holds a total of 39,488 shares of AbbVie Inc which is valued at $2,643,722. AbbVie Inc makes up approx 0.04% of Assetmark Inc’s portfolio.Heritage Wealth Advisors boosted its stake in ABBV in the latest quarter, The investment management firm added 865 additional shares and now holds a total of 6,665 shares of AbbVie Inc which is valued at $443,489. AbbVie Inc makes up approx 0.29% of Heritage Wealth Advisors’s portfolio.Tokio Marine Asset Management Co Ltd reduced its stake in ABBV by selling 1,683 shares or 3.51% in the most recent quarter. The Hedge Fund company now holds 46,225 shares of ABBV which is valued at $3,000,003. AbbVie Inc makes up approx 0.30% of Tokio Marine Asset Management Co Ltd’s portfolio.Stonebridge Capital Management Inc reduced its stake in ABBV by selling 500 shares or 2.82% in the most recent quarter. The Hedge Fund company now holds 17,233 shares of ABBV which is valued at $1,118,422. AbbVie Inc makes up approx 0.49% of Stonebridge Capital Management Inc’s portfolio.Brookstone Capital Management boosted its stake in ABBV in the latest quarter, The investment management firm added 7,885 additional shares and now holds a total of 63,614 shares of AbbVie Inc which is valued at $4,033,764. AbbVie Inc makes up approx 0.52% of Brookstone Capital Management’s portfolio.

AbbVie Inc opened for trading at $67.47 and hit $68.1239 on the upside on Monday, eventually ending the session at $67.39, with a gain of 0.30% or 0.2 points. The heightened volatility saw the trading volume jump to 52,15,360 shares. Company has a market cap of $109,747 M.

On the company’s financial health, AbbVie Inc reported $1.26 EPS for the quarter, beating the analyst consensus estimate by $ 0.06 according to the earnings call on Jul 29, 2016. Analyst had a consensus of $1.20. The company had revenue of $6452.00 million for the quarter, compared to analysts expectations of $6207.43 million. The company’s revenue was up 17.8% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.08 EPS.

Many Wall Street Analysts have commented on AbbVie Inc. AbbVie Inc was Downgraded by Morgan Stanley to ” Equal-Weight” on Jun 8, 2016.

AbbVie Inc. (AbbVie) is a global research-based biopharmaceutical company. The Company develops and markets therapies that address a range of diseases. The Company’s products are focused on treating conditions such as chronic autoimmune diseases including rheumatoid arthritis psoriasis and Crohn’s disease; hepatitis C (HCV); human immunodeficiency virus (HIV); endometriosis; thyroid disease; Parkinson’s disease; complications associated with chronic kidney disease and cystic fibrosis and other health conditions such as low testosterone. AbbVie also has a pipeline of new medicines including over 30 compounds or indications in Phase II or Phase III development across a range of medical specialties such as immunology virology/liver disease oncology renal disease neurological diseases and women’s health. The Company’s product portfolio includes HUMIRA HCV products Additional Virology products Metabolics/Hormones products Endocrinology products and other products.

Leave a Reply

AbbVie Inc - Is it time to Sell?

Top Brokerage Firms are advising their investors on AbbVie Inc. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.